Selpercatinib

塞普替尼

Report date: 2026/02/26 20:00:22
NME

Base Information

Drug NameSelpercatinib
Drug Alias Name塞普替尼Selpeercatinib塞尔帕替尼RetevmoRetsevmo +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitorsVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonists +[6] 
TargetsTyrosine-protein kinase receptor RETVascular endothelial growth factor receptor 3Vascular endothelial growth factor receptor 1 +[6] 
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Poorly Differentiated Thyroid Gland CarcinomaSolid tumours +[34] 
Global Approved IndicationsMedullary thyroid cancer (MTC)Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2020/05/08
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics IncEli Lilly Japan KkQuotient Sciences - Philadelphia Llc +[11] 
Inactive CompaniesLilly Del Caribe Inc
Active IndicationsMedullary thyroid cancer (MTC)Poorly Differentiated Thyroid Gland CarcinomaSolid tumours +[31] 
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyNeoplasms

Other Information

ATC CodeL01
Related LinksDrugBankKEGG